[Genetic performance criteria for valproate in patients with epilepsy].

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

[Genetic performance criteria for valproate in patients with epilepsy].

Likars'ka sprava - 1 Jan 2000

Oros M M

Abstract excerpt

We found a clear correlation between the presence of the CC genotype and genotype combination CC and CT P-glycoproteins rs1045642 and rs1128503 with farmakorezystentnistyu data of patients with valproate (P < 0,01). Also, based on studies demonstrated that the presence of polymorphism TT P-glycop...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Share to Drug Resistance

Share to Epilepsy

Share to Infant

Share to Pharmacogenetics

Share to Treatment Outcome

Share to Valproic Acid

Source

Open in PubMed

Identifiers

PMID: 22416375

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22416375-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Genetic performance criteria for valproate in patients with epilepsy].PMID 22416375Read ↗

[The new algorithm for disease management of patients with epilepsy based on genetic research].Semantic proximity Read ↗

Evaluating the Role of Genetic Variants on first-line antiepileptic drug response in North India: Significance of SCN1A and GABRA1 Gene Variants in Phenytoin Monotherapy and its Serum Drug Levels.Semantic proximity Read ↗

A translational multimodal machine-learning prototype predicting valproate response in epilepsy treatmentSemantic proximity Read ↗

[Pharmacogenetic criteria of drug-resistant epilepsy].Semantic proximity Read ↗

Association of SCN1A, SCN2A, and UGT2B7 Polymorphisms with Responsiveness to Valproic Acid in the Treatment of Epilepsy.Semantic proximity Read ↗

Association of genetic variants in six candidate genes with valproic acid therapy optimization.Semantic proximity Read ↗

Ketogenic diet effectiveness is superior for drug resistant epilepsy with causative genetic mutation than those without genetic etiology.Semantic proximity Read ↗

Genetic and non-genetic factors influencing the therapeutic response of valproic acid in pediatric epileptic patients.Semantic proximity Read ↗

Resistance to valproic acid as predictor of treatment resistance in genetic generalized epilepsiesSemantic proximity Read ↗

Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis.Semantic proximity Read ↗

Effects of UGT1A6 and GABRA1 on Standardized Valproic Acid Plasma Concentrations and Treatment Effect in Children With Epilepsy in China.Semantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis and dose optimization of valproic acid in Chinese southern children with epilepsy: Effect of ABCB1 gene polymorphismSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.